• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Novavax Inc.

Novavax stock surges after striking EU COVID-19 vaccine deal

August 4, 2021 By Brian Buntz

Novavax (NSDQ:NVAX) saw its stock jump more than 20% in afternoon trading after the European Commission agreed to purchase up to 200 million doses of its vaccine.  The Gaithersburg, Md.–based vaccine maker announced in March that its NVX-CoV2373 vaccine was 96.4% effective against the original SARS-CoV-2 strain in a U.K. trial. The efficacy in a later trial […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca plc, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Moderna, Novavax, Novavax Inc., NVX-CoV2373, Pfizer

Novax could have one of the most-effective COVID-19 vaccines

March 12, 2021 By Brian Buntz

Novavax (Gaithersburg, Md.) may not be the best-known vaccine developer, but its COVID-19 vaccine offers performance in line with those from Moderna and Pfizer. Its vaccine was 96.4% effective at preventing COVID-19 caused by the original strain of the virus in a Phase 3 study. The Moderna and Pfizer vaccines offered efficacy in the mid-90% […]

Filed Under: Pharmaceutical Tagged With: BioNTech, Clinical Trials, coronavirus, COVID-19, Moderna, Novavax, Novavax Inc., Pfizer

Drug companies agree not to release COVID-19 vaccine until it’s ready

September 8, 2020 By Sean Whooley

Executives from nine different drug companies today announced a pledge to ensure safety with a potential COVID-19 vaccine. The CEOs of AstraZeneca (NYSE:AZN), BioNTech (NSDQ:BNTX), GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NSDQ:MRNA), Novavax (NSDQ:NVAX), Pfizer (NYSE:PFE) and Sanofi (NYSE:SNY), all of whom are developing vaccine candidates, all signed the pledge, which vows to “uphold the integrity of the scientific process” […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: AstraZeneca plc, BioNTech, coronavirus, COVID-19, Donald Trump, GlaxoSmithKline plc, Johnson and Johnson, Merck, Moderna, Novavax Inc., Pfizer, Sanofi

U.S. paying Novavax $1.6b to ramp up COVID-19 vaccine manufacturing

July 7, 2020 By Sean Whooley

The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax  (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate. Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or, should the […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Funding Roundup, Pharmaceutical Tagged With: coronavirus, COVID-19, Dept. of Health & Human Services (HHS), Novavax Inc., U.S. Department of Defense

Novavax touts nanoparticle RSV vaccine in women of child-bearing age

June 7, 2017 By Sarah Faulkner

Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine. Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pediatrics, Wall Street Beat, Women's Health Tagged With: Novavax Inc.

Diamyd CEO exits over board rift | Personnel moves

April 27, 2011 By MassDevice staff Leave a Comment

MassDevice.com Personnel Moves

Diamyd Medical AB (OTC:DMYDY) and its CEO parted ways after the chief executive had a falling out with the company’s board.

Elisabeth Lindner left her position with the company "due to disagreement with the Board concerning certain important matters," the company said in prepared remarks.

Filed Under: News Well Tagged With: Biosign Technologies Inc., Diamyd Medical AB, Harlan Laboratories Inc., IntraPace Inc., Invacare, Novavax Inc., Personnel Moves, SynapDx Corp.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS